Literature DB >> 9643526

How do mutated oncogenes and tumor suppressor genes cause cancer?

D Grandér1.   

Abstract

In recent decades we have been given insight into the process that transforms a normal cell into a malignant cancer cell. It has been recognised that malignant transformation occurs through successive mutations in specific cellular genes, leading to the activation of oncogenes and inactivation of tumor suppressor genes. The further study of these genes has generated much of its excitement from the convergence of experiments addressing the genetic basis of cancer, together with cellular pathways that normally control important cellular regulatory programmes. In the present review the context in which oncogenes and tumor suppressor genes normally function as key regulators of physiological processes such as proliferation, cell death/apoptosis, differentiation and senescence will be described, as well as how these cellular programmes become deregulated in cancer due to mutations.

Entities:  

Mesh:

Year:  1998        PMID: 9643526     DOI: 10.1007/bf02787340

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  17 in total

Review 1.  Cell differentiation in acute myeloid leukemia.

Authors:  I Olsson; G Bergh; M Ehinger; U Gullberg
Journal:  Eur J Haematol       Date:  1996-07       Impact factor: 2.997

2.  THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS.

Authors:  L HAYFLICK
Journal:  Exp Cell Res       Date:  1965-03       Impact factor: 3.905

Review 3.  Perturbation of cell cycle regulators in human cancer.

Authors:  I Palmero; G Peters
Journal:  Cancer Surv       Date:  1996

Review 4.  A license to kill.

Authors:  A Fraser; G Evan
Journal:  Cell       Date:  1996-06-14       Impact factor: 41.582

Review 5.  Molecular thanatopsis: a discourse on the BCL2 family and cell death.

Authors:  E Yang; S J Korsmeyer
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

Review 6.  Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs).

Authors:  X Graña; E P Reddy
Journal:  Oncogene       Date:  1995-07-20       Impact factor: 9.867

Review 7.  Apoptosis and carcinogenesis.

Authors:  A H Wyllie
Journal:  Eur J Cell Biol       Date:  1997-07       Impact factor: 4.492

8.  Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.

Authors:  D A Alcorta; Y Xiong; D Phelps; G Hannon; D Beach; J C Barrett
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

Review 9.  Telomeres and telomerase in aging and cancer.

Authors:  C B Harley; B Villeponteau
Journal:  Curr Opin Genet Dev       Date:  1995-04       Impact factor: 5.578

10.  ICE/CED-3 proteasesin apoptosis.

Authors:  M Whyte
Journal:  Trends Cell Biol       Date:  1996-07       Impact factor: 20.808

View more
  18 in total

1.  Human AP-endonuclease (Ape1) activity on telomeric G4 structures is modulated by acetylatable lysine residues in the N-terminal sequence.

Authors:  Silvia Burra; Daniela Marasco; Matilde Clarissa Malfatti; Giulia Antoniali; Antonella Virgilio; Veronica Esposito; Bruce Demple; Aldo Galeone; Gianluca Tell
Journal:  DNA Repair (Amst)       Date:  2018-11-22

Review 2.  Cancer metabolism: what we can learn from proteomic analysis by mass spectrometry.

Authors:  Weidong Zhou; Lance A Liotta; Emanuel F Petricoin
Journal:  Cancer Genomics Proteomics       Date:  2012-11       Impact factor: 4.069

Review 3.  Targeting the perpetrator: breast cancer stem cell therapeutics.

Authors:  Arindam Pal; Kelli E Valdez; Martha Z Carletti; Fariba Behbod
Journal:  Curr Drug Targets       Date:  2010-09       Impact factor: 3.465

Review 4.  Apoptosis and cell growth inhibition as antitumor effector functions of interferons.

Authors:  H Strander
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

5.  Effects of 5-Aza-CdR on cell proliferation of breast cancer cell line MDA-MB-435S and expression of maspin gene.

Authors:  Bo Zhang; Tao Huang; Ke Liu; Jianying Chen; Guobin Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-10

6.  Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A.

Authors:  Haiquan Lu; Xinqun Li; Zhongguang Luo; Jie Liu; Zhen Fan
Journal:  Mol Cancer Ther       Date:  2013-08-06       Impact factor: 6.261

Review 7.  Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms.

Authors:  A Albini
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

Review 8.  PET-specific parameters and radiotracers in theoretical tumour modelling.

Authors:  Matthew Jennings; Loredana G Marcu; Eva Bezak
Journal:  Comput Math Methods Med       Date:  2015-02-19       Impact factor: 2.238

9.  Searching for electrical properties, phenomena and mechanisms in the construction and function of chromosomes.

Authors:  Ivan Kanev; Wai-Ning Mei; Akira Mizuno; Kristi Dehaai; Jennifer Sanmann; Michelle Hess; Lois Starr; Jennifer Grove; Bhavana Dave; Warren Sanger
Journal:  Comput Struct Biotechnol J       Date:  2013-06-27       Impact factor: 7.271

10.  MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands.

Authors:  Eun Joo Chung; Mary Ellen Urick; Naamit Kurshan; William Shield; Hiroaki Asano; Paul D Smith; Bradley S Scroggins; Jeffrey Burkeen; Deborah E Citrin
Journal:  Int J Oncol       Date:  2013-04-10       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.